MicroRNA-mediated regulation of gene expression is affected by disease-associated SNPs within the 3′-UTR via altered RNA structure

RNA Biology

Volumn 9, Issue 6, 2012, Pages 924-937

  Haas, Ulrike ^a   Sczakiel, Georg ^a   Laufer, Sandra D ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AGTR1; Cardiovascular disease; miR SNP; miRNA; MRAS; RNA secondary structure analysis; SNP

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; MICRORNA; MICRORNA 135; MICRORNA 155; MICRORNA 195; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; IN VITRO STUDY; PREDICTION; PROTEIN CLEAVAGE; REPORTER GENE; RNA BINDING; RNA FOLDING; RNA PROCESSING; RNA STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863471303     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.20497     Document Type: Article

References (63)

1. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001; 107:823-6; PMID:11779458; http://dx.doi.org/10.1016/S0092-8674(01)00616-X.
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002.
3. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008; 132:9-14; PMID:18191211; http://dx.doi.org/10.1016/j.cell.2007.12.024.
4. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9:102-14; PMID:18197166; http://dx.doi.org/10.1038/nrg2290.
5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-54; PMID:8252621; http://dx.doi.org/10.1016/0092-8674(93)90529-Y.
6. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34:140-4; PMID:16381832; http://dx.doi.org/10.1093/nar/gkj112.
7. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol 2005; 3:85; PMID:15723116; http://dx.doi.org/10.1371/ journal.pbio.0030085.
8. Wang Y, Stricker HM, Gou D, Liu L. MicroRNA: past and present. Front Biosci 2007; 12:2316-29; PMID:17127242; http://dx.doi.org/10.2741/2234.
9. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126:1203-17; PMID:16990141; http://dx.doi.org/10.1016/j.cell.2006.07.031.
10. Couzin J. MicroRNAs make big impression in disease after disease. Science 2008; 319:1782-4; PMID:18369134; http://dx.doi.org/10.1126/science.319.5871. 1782.
11. Jeyaseelan K, Herath WB, Armugam A. MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets 2007; 11:1119-29; PMID:17665982; http://dx.doi.org/10.1517/14728222.11.8.1119.
12. Li M, Li J, Ding X, He M, Cheng SY. microRNA and cancer. AAPS J 2010; 12:309-17; PMID:20422339; http://dx.doi.org/10.1208/s12248-010-9194-0.
13. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present and potential future. Mol Cancer Ther 2008; 7:3655-60; PMID:19074842; http://dx.doi.org/10. 1158/1535-7163.MCT-08-0586.
14. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 2007; 35:4535-41; PMID:17584784; http://dx.doi.org/10.1093/nar/gkm480.
15. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, L'Abbe D, et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 2008; 29:1710-6; PMID:18356149; http://dx.doi.org/10. 1093/carcin/bgn073.
16. Saunders MA, Liang H, Li WH. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 2007; 104:3300-5; PMID:17360642; http://dx.doi.org/10.1073/pnas.0611347104.
17. Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 2006; 38:1452-6; PMID:17072316; http://dx.doi.org/10.1038/ng1910.
18. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008; 29:1306-11; PMID:18477647; http://dx.doi.org/10.1093/carcin/bgn116.
19. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009; 10:399-416; PMID:19290790; http://dx.doi.org/10.2217/ 14622416.10.3.399.
20. Bandiera S, Hatem E, Lyonnet S, Henrion-Caude A. microRNAs in diseases: from candidate to modifier genes. Clin Genet 2010; 77:306-13; PMID:20132241; http://dx.doi.org/10.1111/j.1399-0004.2010.01370.x.
21. Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle 2008; 7:2570-83; PMID:18719369; http://dx.doi.org/10.4161/cc.7.16.6524.
22. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008; 29:579-84; PMID:18192692; http://dx.doi.org/10. 1093/carcin/bgm304.
23. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 2008; 14:7956-62; PMID:19047128; http://dx.doi.org/ 10.1158/1078-0432.CCR-08-1199.
24. Kontorovich T, Cohen Y, Nir U, Friedman E. Promoter methylation patterns of ATM ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat 2009; 116:195-200; PMID:18642075; http://dx.doi.org/10.1007/s10549-008-0121-3.
25. Brendle A, Lei H, Brandt A, Johansson R, Enquist K, Henriksson R, et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 2008; 29:1394-9; PMID:18550570; http://dx.doi.org/10.1093/carcin/bgn126.
26. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005; 310:317-20; PMID:16224024; http://dx.doi.org/10.1126/science.1116502.
27. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibé B, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 2006; 38:813-8; PMID:16751773; http://dx.doi.org/10.1038/ng1810.
28. Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 2011; 43:242-5; PMID:21278745; http://dx.doi.org/10.1038/ng.762.
29. Baudin B. Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 2005; 90:277- 82; PMID:15640279; http://dx.doi.org/10.1113/ expphysiol.2004.028456.
30. Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 2007; 113:210-26; PMID:17125841; http://dx.doi.org/10.1016/j.pharmthera.2006.10.001.
31. Rosskopf D, Michel MC. Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. Pharmacol Rev 2008; 60:513-35; PMID:19074621; http://dx.doi.org/10.1124/pr.108.000612.
32. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24:63-9; PMID:8021009.
33. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, et al. The human angiotensin II type 1 receptor + 1,166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 2007; 282:24262-9; PMID:17588946; http://dx.doi.org/10.1074/jbc.M701050200.
34. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281:18277-84; PMID:16675453; http://dx.doi.org/10.1074/jbc. M601496200.
35. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007; 81:405-13; PMID:17668390; http://dx.doi.org/10.1086/519979.
36. Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism and AT1R expression in young untreated hypertensives. Am J Hypertens 2011; 24:241-6; PMID:20966899; http://dx.doi.org/10.1038/ajh.2010.211.
37. Mishra PK, Tyagi N, Kumar M, Tyagi SC. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 2009; 13:778-89; PMID:19320780; http://dx.doi.org/10.1111/j.1582-4934.2009.00744.x.
38. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27:91-105; PMID:17612493; http://dx.doi.org/10.1016/j.molcel.2007. 06.017.
39. Kretschmer-Kazemi Far R, Sczakiel G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 2003; 31:4417-24; PMID:12888501; http://dx.doi.org/10.1093/nar/gkg649.
40. Sczakiel G, Kretschmer-Kazemi Far R. The role of target accessibility for antisense inhibition. Curr Opin Mol Ther 2002; 4:149-53; PMID:12044036.
41. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005; 436:214-20; PMID:15951802; http://dx.doi.org/10.1038/nature03817.
42. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet 2007; 39:1278-84; PMID:17893677; http://dx.doi.org/10.1038/ng2135.
43. Long D, Lee R, Williams P, Chan CY, Ambros V, Ding Y. Potent effect of target structure on microRNA function. Nat Struct Mol Biol 2007; 14:287-94; PMID:17401373; http://dx.doi.org/10.1038/nsmb1226.
44. Robins H, Li Y, Padgett RW. Incorporating structure to predict microRNA targets. Proc Natl Acad Sci USA 2005; 102:4006-9; PMID:15738385; http://dx.doi.org/10.1073/pnas.0500775102.
45. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004; 10:1507-17; PMID:15383676; http://dx.doi.org/10.1261/rna.5248604.
46. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36:149-53; PMID:18158296; http://dx.doi.org/10.1093/nar/gkm995.
47. Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res 1999; 27:4328-34; PMID:10536139; http://dx.doi.org/10.1093/nar/27.22.4328.
48. Kretschmer-Kazemi Far R, Nedbal W, Sczakiel G. Concepts to automate the theoretical design of effective antisense oligonucleotides. Bioinformatics 2001; 17:1058-61; PMID:11724735; http://dx.doi.org/10.1093/bioinformatics/17.11.1058.
49. Overhoff M, Alken M, Kretschmer-Kazemi Far R, Lemaitre M, Lebleu B, Sczakiel G, et al. Local RNA target structure influences siRNA efficacy: a systematic global analysis. J Mol Biol 2005; 348:871-81; PMID:15843019; http://dx.doi.org/10.1016/j.jmb.2005.03.012.
50. Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, Hall AS, et al.; Italian Atherosclerosis, Thrombosis and Vascular Biology Working Group; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium; Cardiogenics Consortium. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 2009; 41:280-2; PMID:19198612; http://dx.doi.org/10.1038/ng.307.
51. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103:18255-60; PMID:17108080; http://dx.doi.org/10.1073/pnas.0608791103.
52. Sõber S, Laan M, Annilo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun 2010; 391:727-32; PMID:19944075; http://dx.doi.org/ 10.1016/j.bbrc.2009.11.128.
53. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005; 33:1290-7; PMID:15741182; http://dx.doi.org/10.1093/ nar/gki200.
54. Du Q, Thonberg H, Zhang HY, Wahlestedt C, Liang Z. Validating siRNA using a reporter made from synthetic DNA oligonucleotides. Biochem Biophys Res Commun 2004; 325:243-9; PMID:15522225; http://dx.doi.org/10.1016/j.bbrc.2004.09.222.
55. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR Jr. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 2007; 104:13513-8; PMID:17686970; http://dx.doi.org/10.1073/pnas.0706217104.
56. Jacobsen A, Wen J, Marks DS, Krogh A. Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res 2010; 20:1010-9; PMID:20508147; http://dx.doi.org/10.1101/gr.103259.109.
57. Leibovich L, Mandel-Gutfreund Y, Yakhini Z. A structural-based statistical approach suggests a cooperative activity of PUM1 and miR-410 in human 3′-untranslated regions. Silence 2010; 1:17; PMID:20860814; http://dx.doi.org/10.1186/1758-907X-1-17.
58. Kedde M, van Kouwenhove M, Zwart W, Oude Vrielink JA, Elkon R, Agami R. A Pumilio-induced RNA structure switch in p27-3′ UTR controls miR-221 and miR-222 accessibility. Nat Cell Biol 2010; 12:1014-20; PMID:20818387; http://dx.doi.org/10.1038/ncb2105.
59. Picard V, Ersdal-Badju E, Lu A, Bock SC. A rapid and efficient one-tube PCR-based mutagenesis technique using Pfu DNA polymerase. Nucleic Acids Res 1994; 22:2587-91; PMID:8041621; http://dx.doi.org/10.1093/nar/22.13.2587.
60. Benecke H. RNA/Protein & Protein/Protein-Interaktionen innerhalb des U11/U12 di-snRNP Partikels des U12-abhängigen Spleißosoms aus HeLa-Zellen. Max-Planck-Institut für biophysikalische Chemie, Abteilung Zelluläre Biochemie. Göttingen 2004.
61. Eckardt S, Romby P, Sczakiel G. Implications of RNA structure on the annealing of a potent antisense RNA directed against the human immunodeficiency virus type 1. Biochemistry 1997; 36:12711- 21; PMID:9335527; http://dx.doi.org/10.1021/bi9707234.
62. Mathews DH, Sabina J, Zuker M, Turner DH. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 1999; 288:911-40; PMID:10329189; http://dx.doi.org/10.1006/jmbi.1999.2700.
63. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31:3406-15; PMID:12824337; http://dx.doi.org/10.1093/nar/gkg595.